Keywords: cpmp, backs, approval, lamivudine, hbv, glaxo, wellcome

CPMP backs approval of lamivudine for HBV

Article | 29 April 1999

Print This

Glaxo Wellcome and BioChem Pharma's nucleoside analog Zeffix(lamivudine) has been recommended for approval as a treatment for hepatitis B ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in